Jun 26th, 2019 - Dosing See Important Safety Information, including BOXED WARNING.
Patients treated with infliximab products are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
Official health care professional site from AbbVie Inc. Find safety and prescribing information, including BOXED WARNING, for HUMIRA (adalimumab).
Find efficacy and prescribing information for Enbrel® (etanercept) and learn how the medication may help your patients.
Patients should be tested for latent TB before and during treatment with REMICADE ®. 1,2 Treatment for latent infection should be initiated prior to treatment with REMICADE ®. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis and pneumocystosis.
Remsima™ is the world's first biosimilar monoclonal antibody (mAb) medication to be approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Remsima™ was approved by the EMA in September 2013 and by U.S. FDA in April 2016, for treatment of patients with a number of ...
Systemic Lupus Erythematosus. ... Acthar® Gel (repository corticotropin injection) is an adrenocorticotropic hormone (ACTH) analogue used for: Adjunctive therapy for short?term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis ...
Read about a treatment option for moderately to severely active CD if response to therapy was inadequate RA, PsA, ankylosing spondylitis.
See risks & benefits. Get information for healthcare professionals on treating moderate to severe rheumatoid arthritis with XELJANZ XR® (tofacitinib).
Learn more about Taltz (ixekizumab), an indicated treatment for adults with moderate to severe plaque psoriasis, -- and now approved for adults with active psoriatic arthritis.
Learn about Otezla (apremilast), a treatment for moderate to severe plaque psoriasis or active psoriatic arthritis. Review the mechanism of action (MOA), the clinical trial program, efficacy data, and safety. Access educational materials for your patients and information about prescribing and starting patients on Otezla.
Learn about SIMPONI ARIA® (golimumab) for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Please see full Prescribing Information for SIMPONI ARIA®, including Boxed WARNING.
STELARA®, available as 45 mg and 90 mg, is a subcutaneous injection intended for use under the guidance and supervision of a physician with patients who will be closely monitored and have regular follow-up visits with a physician. If a physician determines that it is appropriate, a patient may self-inject or a caregiver may ...
Our site offers info for healthcare providers treating patients with moderate to severe rheumatoid arthritis. See Important Safety Info and Prescribing Info.
Risankizumab (ABBV-066) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease, ulcerative colitis, atopic dermatitis and psoriatic arthritis.
Learn about COSENTYX (secukinumab), the first fully human monoclonal antibody to selectively target IL-17A approved for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Learn how COSENTYXÂ® (secukinumab) can provide long-lasting treatment for moderate to severe plaque psoriasis and inhibit the progression of joint damage in psoriatic arthritis.
Learn how COSENTYX® (secukinumab) is an effective treatment for psoriatic arthritis (PsA) by reviewing IL-17A mechanism of action & clinical trial information.
Learn about the mechanism of action of HUMIRA (adalimumab), and how it’s used for treatment of certain immune-mediated diseases.
Dec 10th, 2019 - XELJANZ/XELJANZ XR is a Janus kinase (JAK) inhibitor. Rheumatoid Arthritis: XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMA...